Strategic CDMO Scorpius BioManufacturing operates as an integrated CDMO with capabilities in analytical testing, process development, and manufacturing for biologics, presenting opportunities to upsell full-package development-to-commercial manufacturing services to biotech and pharma clients seeking streamlined clinical to commercial biologics capabilities.

Recent partnerships Recent announcements of partnerships and collaborations with Tivic Health, Celltheon, and others indicate active market engagement and validation of Scorpius capabilities, suggesting opportunities to approach similar mid-to-late stage biotech companies seeking GMP manufacturing validation and specialized cell line or transposase-based platform support.

Leadership expansion Board and leadership additions, including the appointment of Tan Sze Thuan and a growing executive team, signal a strategic push and credibility lift that can be leveraged when approaching investors or sponsors looking for experienced governance and growth potential in a specialized CDMO.

Early-stage focus With a small employee base and revenue in the low single digits, Scorpius presents as a nimble partner for early-stage biotech programs requiring rapid development, scalable analytical and manufacturing workflows, and flexible collaboration models before larger CDMOs are engaged.

Global collaboration Evidence of client engagements and international partnerships, plus access to U.S.-based facilities and a technology stack that includes cloud, analytics, and ERP tools, positions Scorpius as a compelling partner for global biotech companies seeking compliant, plug‑and‑play biomanufacturing capabilities and transparent collaboration.